9 Participants Needed

Advanced Imaging for Radiation Planning in Non-Small Cell Lung Cancer

SK
SF
Overseen BySteven Feigenberg, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Xemed LLC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial uses advanced imaging to help treat lung cancer patients. It aims to protect healthy lung tissue while effectively targeting the tumor.

Do I need to stop my current medications for this trial?

The trial protocol does not specify if you need to stop taking your current medications. However, since the trial involves MRI scans, you should inform the study team about all medications you are taking, as some might interact with the imaging process.

What data supports the idea that Advanced Imaging for Radiation Planning in Non-Small Cell Lung Cancer is an effective treatment?

The available research shows that Hyperpolarized Xenon-129 MRI is a promising tool for lung imaging, particularly in assessing lung function and ventilation. Although most studies focus on non-cancerous lung diseases, the ability to evaluate key lung processes suggests potential benefits for lung cancer patients. The research highlights its unique capability to provide detailed 3D images of lung function, which could improve treatment planning for lung cancer. However, there is no direct comparison to other treatments for lung cancer in the provided data.12345

What safety data exists for Hyperpolarized Xenon-129 MRI?

The safety and tolerability of Hyperpolarized Xenon-129 MRI have been assessed in various studies, primarily focusing on non-malignant pulmonary diseases and pediatric lung function. The research indicates that it is a promising imaging modality, but its safety in specific populations, such as children with cystic fibrosis, has not been rigorously assessed. Overall, it is considered a noninvasive diagnostic tool with potential applications in lung imaging.13567

Is Hyperpolarized Xenon-129 MRI a promising treatment for lung cancer?

Yes, Hyperpolarized Xenon-129 MRI is a promising treatment for lung cancer because it helps doctors see how well the lungs are working and can guide radiation therapy to avoid damaging healthy lung areas.12358

Eligibility Criteria

This trial is for adults over 18 with non-small cell lung cancer who are set for radiation therapy. It's also open to those with severe COPD or a history of successful prior lung cancer treatment and now facing secondary lung cancer. Exclusions include pregnancy, inability to consent, unstable living situations, substance dependence, large body size or chest that won't fit in an MRI machine, metal implants, and certain health conditions.

Inclusion Criteria

I had successful radiation for lung cancer and now have a second lung cancer.
I have new lung cancer and severe COPD, and am planned for radiation therapy.
I am over 18 and diagnosed with non-small lung cancer, scheduled for radiation therapy.

Exclusion Criteria

You have a metal device implanted in your body.
A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study
If you have any reason that makes it unsafe for you to have an MRI scan.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive radiation therapy with functional lung avoidance using hyperpolarized xenon-129 MRI

1 year
Regular visits for radiation therapy sessions and imaging

Follow-up

Participants are monitored for safety and effectiveness after treatment, including imaging and lung function tests

6 months
Follow-up imaging and lung function tests at 6 months

Open-label extension (optional)

Participants may continue to be monitored for long-term safety and lung function

Long-term

Treatment Details

Interventions

  • Hyperpolarized Xenon-129 MRI
Trial OverviewThe study tests hyperpolarized xenon-129 MRI's ability to map healthy vs compromised lung tissue in patients undergoing radiation therapy for lung cancer. The goal is to tailor treatment plans that minimize damage to functioning lungs and reduce the risk of radiation pneumonitis.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Standard-of-care Radiation Therapy for lung cancer using HXe MRI for diagnosis.Experimental Treatment1 Intervention
Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study, where they will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. However, for this part of the study, subjects will still follow the standard-of-care radiation treatment plan. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
Group II: Guided Radiation Therapy for lung cancer using HXe MRI for functional lung avoidance and diagnosis.Experimental Treatment1 Intervention
Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.

Hyperpolarized Xenon-129 MRI is already approved in United Kingdom, United States for the following indications:

🇬🇧
Approved in United Kingdom as Hyperpolarized Xenon-129 MRI for:
  • Respiratory diseases including asthma, COPD, cystic fibrosis, pulmonary vascular disease, idiopathic pulmonary fibrosis, lung cancer, and lymphangioleiomyomatosis
🇺🇸
Approved in United States as Hyperpolarized Xenon-129 MRI for:
  • Clinical approval pending; potential indications include respiratory diseases such as asthma, COPD, cystic fibrosis, pulmonary vascular disease, idiopathic pulmonary fibrosis, lung cancer, and lymphangioleiomyomatosis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Xemed LLC

Lead Sponsor

Trials
8
Recruited
370+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Findings from Research

Hyperpolarized 129 Xenon-MRI (HP 129 Xe MRI) is a new imaging technique that can assess both how well air moves in and out of the lungs (ventilation) and how effectively gases are transferred in the lungs.
While most studies have focused on non-cancer lung diseases, HP 129 Xe MRI shows great potential for improving the management and understanding of lung cancer by evaluating these key lung functions.
Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI.Song, EJ., Kelsey, CR., Driehuys, B., et al.[2022]
Hyperpolarized (HP) noble gas MRI, particularly using 129Xe, has shown promising results in assessing lung ventilation and regional lung physiology, making it a potential game-changer in pulmonary medicine.
Despite being limited to select academic institutions currently, advancements in polarizer technology suggest that HP 129Xe MRI could soon become more widely available for clinical use, enhancing the diagnostic capabilities for lung conditions.
The role of hyperpolarized 129xenon in MR imaging of pulmonary function.Ebner, L., Kammerman, J., Driehuys, B., et al.[2018]
The continuous flow-type hyperpolarizing (CF-HP) system allows for effective lung imaging using hyperpolarized (129)Xe MRI at very low concentrations of xenon, minimizing the anesthetic effects and reducing xenon consumption.
Using a 70% xenon gas mixture resulted in better signal-to-noise ratios for both gas and dissolved-phase images compared to a 3% mixture, although the apparent diffusion coefficient (ADC) was higher with the 3% mixture, indicating a complex relationship between concentration and imaging quality.
Hyperpolarized 129 Xe MRI of the mouse lung at a low xenon concentration using a continuous flow-type hyperpolarizing system.Wakayama, T., Kitamoto, M., Ueyama, T., et al.[2015]

References

Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI. [2022]
The role of hyperpolarized 129xenon in MR imaging of pulmonary function. [2018]
Hyperpolarized 129 Xe MRI of the mouse lung at a low xenon concentration using a continuous flow-type hyperpolarizing system. [2015]
Pulmonary hyperpolarized noble gas MRI: recent advances and perspectives in clinical application. [2017]
Brain Imaging Using Hyperpolarized 129Xe Magnetic Resonance Imaging. [2019]
Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis. [2022]
Small animal imaging with hyperpolarized 129Xe magnetic resonance. [2019]
A pilot study of function-based radiation therapy planning for lung cancer using hyperpolarized xenon-129 ventilation MRI. [2022]